Formulary guidance and transparency from P&T to point of care

Radar On Market Access: Immuno-Oncology Drugs

Posted by Matt Breese on Apr 5, 2018

As more oncology immunotherapies enter the U.S. market, manufacturers are working to effectively compete and gain market share, according to AIS Health.
Stephen Cichy at Monarch Specialty Group, LLC, points out that the definition of cancer is changing. The increased use of predictive biomarkers is leading to “an increase in the number of personalized medicines that can specifically target unique cancer populations.”
Read More

Topics: Industry Trends, Market Access, Product Release

Radar On Market Access: Pediatric and Adult Vaccines

Posted by Matt Breese on Mar 29, 2018

A concerted effort is underway to develop hepatitis A and B vaccines and vaccines against human papilloma virus (HPV) to prevent the incidence of certain types of cancers, according to AIS Health .
Though the return on investment for any given vaccine-related venture is anything but assured, vaccine franchises are becoming a viable source of revenue for many companies. The overall world vaccines market is predicted to grow from $34 billion in 2017 to $49 billion by 2022, according to an August 2017 study from market-research company MarketsandMarkets. 
Read More

Topics: Industry Trends, Market Access, Product Release

Perspectives on 2018 Pipeline

Posted by Matt Breese on Feb 27, 2018

The rise of CAR-T and other gene therapies, newly identified oncology targets and next-generation sequencing will shape the pipeline for 2018.
With the first CAR T-cell therapy approved, this new form of immunotherapy has a bright future. Yet drug companies also need to respond to worrisome side effects, such as severe cytokine release syndrome.
Read More

Topics: Specialty, Industry Trends, Product Release

Trends That Matter for Promising Drugs in 2018

Posted by Matt Breese on Feb 22, 2018

FDA’s Center for Drug Evaluation and Research (CDER) approved 46 new drugs in 2017, more than doubling the number of novel medications approved in 2016.

Among the drugs that have been recently launched or will be launched soon, Dupixent, Ocrevus and Imfinizi top the most promising drugs in 2018, according to IgeaHub, a pharmaceutical club for industry influencers. 

Read More

Topics: Industry Trends, Product Release, Branding & Marketing

Trends That Matter for Product Launch

Posted by Matt Breese on Feb 8, 2018

When launching new products, pharmaceutical companies should bring an outcome rather than just a product to market, according to a new study from the professional services company Accenture.

Findings from the study, titled "Product Launch: The Patient Has Spoken," suggest that a medication's benefits are the key factors patients consider when looking at new products. More than 69% of patients think the benefits are more important than the brand of the product. 

Read More

Topics: Product Release, Branding & Marketing

Perspectives on R&D Budgets

Posted by Matt Breese on Jan 30, 2018

To boost innovation and meet public expectations, pharmaceutical and biotechnology industry need to increase collaboration in drug development, says Steve Arlington, president of the Pistoia Alliance. He called collaboration “the only truly viable model,” as developing a new drug normally takes 12 to 15 years at an estimated $2.7 billion cost .
Innovation requires work from multi-disciplinary teams of multiple entities and different geographies. Collaboration will not only accelerate drug discovery, but also make R&D budget go further — and help prove the value of newly approved drugs to payers once they come to market. 
Read More

Topics: Industry Trends, Product Release, Provider

Trends That Matter for Breast Cancer Treatment

Posted by Matt Breese on Jan 25, 2018

In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is a new treatment for breast cancer.

The FDA recently approved the use of Lynparza (olaparib tablets) to treat patients with metastasized breast cancer and whose tumors have a specific inherited genetic mutation. Lynparza becomes the first PARP inhibitor approved for breast cancer and the first drug for treatment of patients with a BRCA mutation. 

Read More

Topics: Industry Trends, Product Release

Formulary Search Update: December 2016

Posted by Stu Allen on Dec 16, 2016

MMIT is committed to regularly enhancing its products – both our data and our software. A new update for MMIT's free Formulary Search application is now available for iPhone, iPad, and Android users.  These updates are also available on the web @

Read More

Topics: Product Release

The Devil is in the Details

Posted by Stu Allen on Dec 9, 2016

Complexities in Formulary Coverage and the Use of Derived Data Elements

It’s no secret that over the past decade or so the complexities contained within formulary drug coverage have skyrocketed.  As drugs become more specialized and higher cost, the rules around which patientscan get these products covered by their insurance providers and at what copay often read like a complicated choose your own adventure novel (and some of these policy documents truly are novels!). 

Read More

Topics: Specialty, Market Access, Product Release, Data & Analytics

Formulary Search 2.5 Years In

Posted by Stu Allen on Sep 12, 2016

With the Formulary Search (Android, Apple, Web) app turning 2 ½ I thought I’d take a minute to recap progress made in the tool over its relatively young lifespan as well as provide some insight into what the evolution of the tool has taught MMIT over that same time period.

Read More

Topics: Market Access, Product Release, Data & Analytics